[Use of fluconazole as antimycotic prophylaxis in radiotherapy of patients with head and neck tumors].
The aim of the present study was to investigate the incidence of Candida stomatitis and resulting interruptions in radiation therapy in 50 patients suffering from squamous cell carcinomas of head and neck region receiving fluconazole (100 mg/d) in comparison to a historical control group without specific prophylaxis. 20 of the control patients (40%) demonstrated Candida stomatitis with 7 of them (14%) requiring interruptions of radiation therapy. In contrast, none of the patients with fluconazole had evidence of Candida stomatitis and subsequent interruption of anticancer therapy. Laboratory monitoring for the presence of Candida species was performed in 15 other patients before and after therapy with fluconazole. Candida albicans was identified less frequently after therapy when compared to the pretreatment status. However, C. glabrata and C. krusei were isolated in some of the patients probably due to decreased drug susceptibility of these species. The results demonstrate the clinical usefulness of prophylactic fluconazole applications in patients suffering from head and neck tumors with the aim to reduce Candida stomatitis and resulting interruptions in radiation therapy.
Mücke
R
R
Zentrum für Radiologie, Universität Rostock, BR Deutschland.
Kaben
U
U
Libera
T
T
Knauerhase
H
H
Ziegler
P G
PG
Hamann
D
D
Strietzel
M
M
D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000302:isolation & purification; D002176:Candida albicans / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000453:epidemiology / Q000517:prevention & control*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D015725:Fluconazole / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D015994:Incidence; D011878:Radiotherapy / Q000009:adverse effects
D000935:Antifungal Agents; D015725:Fluconazole